Note: This is an update to a January 2020 post to include Lupin's investigational agent in phase 3 trials. Roche’s reference product Lucentis® (ranibizumab) seems to be the next likely target for biosimilar competition. Sales of the drug in the US were last reported to be $1.5 billion in 2017, but Roche’s revenues from Lucentis … Continue reading Who Are the Key Lucentis Biosimilar Players to Watch?
